A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxych loroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19)
2 very small studies with hospitalized patients in Taiwan.
RCT with 21 treatment and 12 SOC patients. No mortality, or serious adverse effects. Median time to negative RNA 5 days versus 10 days SOC, p
=0.4. Risk of PCR+ at day 14, RR 0.76, p
This paper also reports on a small retrospective study with 12 of 28 HC
Q patients and 5 of 9 in the control group being PCR- at day 14, RR 1.29, p
no virological cure, ↓24.0%, p=0.71
time to viral-, ↓50.0%, p=0.40, median time to PCR-